Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBIT (2022 - 2025)

Atara Biotherapeutics' EBIT history spans 4 years, with the latest figure at -$31.6 million for Q4 2025.

  • For Q4 2025, EBIT fell 158.58% year-over-year to -$31.6 million; the TTM value through Dec 2025 reached $6.9 million, up 108.23%, while the annual FY2025 figure was $6.9 million, 108.23% up from the prior year.
  • EBIT reached -$31.6 million in Q4 2025 per ATRA's latest filing, down from -$3.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $38.8 million in Q1 2025 to a low of -$88.2 million in Q1 2022.
  • Average EBIT over 4 years is -$39.6 million, with a median of -$31.8 million recorded in 2022.
  • The largest YoY upside for EBIT was 224.18% in 2025 against a maximum downside of 158.58% in 2025.
  • A 4-year view of EBIT shows it stood at -$75.5 million in 2022, then increased by 20.62% to -$60.0 million in 2023, then surged by 79.65% to -$12.2 million in 2024, then crashed by 158.58% to -$31.6 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EBIT are -$31.6 million (Q4 2025), -$3.6 million (Q3 2025), and $3.2 million (Q2 2025).